Omada Health Inc. (OMDA) Dividend Safety Gauge & 10-Year DRIP Compounder

The Roarable RQD Score is 55 out of 100, graded D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim," per the Roarable RQD rating. The score is built from five pillars:

• Fundamental Cash Engine: 13 / 20. Per the Roarable RQD rating, this reflects ROIC of -15.7% and an FCF yield of 1.41%. For a prospective investor, negative ROIC means the business is not currently earning returns above its capital base, and a 1.41% FCF yield is a thin cash return relative to the $19.65 price.
• Whale 13F Flow: 9 / 20. The rating describes this pillar as institutional accumulation and options positioning. The source data does not include 13F holder detail (see Analyst View section), so the pillar score cannot be traced to specific holders here.
• Insider Conviction: 6 / 20. The rating describes SEC Form 4 and Congressional PTR cluster flow. No insider transaction records are supplied in the source data, so the weak score is not independently verifiable from this dossier.
• Macro Regime Fit: 11 / 20. Per the rating, beta is 1.0 and sector sensitivity is reflected in this pillar. Per the market data, beta is 1.0, meaning the stock is expected to move in line with the broader market.
• Forensic Balance Sheet: 16 / 20. The strongest pillar, per the rating: Altman Z 8.93, Piotroski F 7/9, and Debt/Equity 0.5. This indicates a relatively sound balance sheet even though the operating business is loss-making.

Taken together, the rating points to a business with a stronger balance sheet than its earnings profile would suggest. Upside drivers would need to come from a turn toward positive ROIC and cash generation; the rating's valuation tradeoff is that the stock's price already reflects significant expectations relative to current returns. Because the verdict is a Sell/Trim rating, the rating itself flags more downside risk than upside in its current form.

Omada Health Inc. (OMDA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry, per the company profile. The source data does not describe its products, customers, or revenue model. The market capitalization is $1.2B, per the company profile and market data.

Per the SEC financials, revenue grew from $122.8M in FY 2023 to $260.2M in FY 2025, while operating losses narrowed from $-66.0M to $-12.0M. Per the market data, the gross margin is 65.7%, the operating margin is -4.6%, and the net margin is -4.9%. ROIC is -15.7%. The Altman Z-Score is 8.93 and the Piotroski F-Score is 7/9, both per the Roarable RQD rating, with Debt/Equity at 0.5. Reported cash rose to $222.0M in FY 2025, per the SEC financials.

Per the news wire, six items reference OMDA: a Yahoo Finance piece questioning long-term targets and valuation; a Seeking Alpha piece titled that it shows promising growth but questions the moat; a Simply Wall St piece on renewed attention; a TradingView report that Freedom Capital Markets maintains a Buy rating with a $35 price target; a kalkine.ca report that the stock slid 10.1% on an earnings tag; and an Investing.com UK report that Citizens reiterated its rating ahead of Q3 results. The news wire shows mixed sentiment, with several items flagged YELLOW and one flagged GREEN.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

• What is the company's product mix and revenue model behind the $260.2M FY 2025 revenue figure?
• What drove the earnings decline cited in the kalkine.ca report, and what were the actual EPS and forward estimates?
• Why is FY 2025 FCF positive at $16.9M while FY 2025 net income is $-12.8M, and what is the cash bridge?
• What are the debt balances, since the debt field is reported as N/A for all periods?
• What institutional and insider holdings underpin the whale and insider pillar scores?